4DMedical sees its stock climb in afternoon trade after reporting a 23% year-on-year rise in full-year operating revenue to $7.2 million. The uplift comes from higher paid scan volumes rather than one-off deals or licensing windfalls. Investors push the share price up 10.5% to $3.55 by 2pm.
The company’s total scan analysis volumes, including its CT:VQ lung imaging software, hit 105,970 scans in the fourth quarter, a 43% increase on the same quarter last year. Full-year scan volume reaches 344,075, a 77% jump from the prior year that reflects stronger clinical adoption. Revenue growth is closely tied to this higher throughput, indicating customers are using the platform more frequently as it embeds into workflows.
Growth is attributed to heavier utilisation by existing customers, not just new sign-ups, suggesting deeper integration of 4DMedical’s technology in routine practice. Expanded screening programmes in Australia and Brazil add another leg of volume growth, broadening the company’s geographic and clinical footprint. Continued commercial progress for CT:VQ, its flagship imaging analysis product, underpins these numbers and signals that product-led expansion is driving both volume and revenue momentum.
